Free tool
FAERS Monitor: Cerdelga
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205494 or its brand name (Cerdelga, Eliglustat Tartrate). Reports on generic versions are filed under their own applications.
Reports
1,659
Serious
480
29% of reports
Hospitalization
215
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- weight increased175
- product dose omission in error162
- weight decreased150
- fatigue79
- product dose omission issue76
- dyspepsia54
- arthralgia53
- fall53
- nausea51
- dizziness45
- off label use43
- covid-1942
- diarrhoea41
- nasopharyngitis41
- headache39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 7 |
| 2015 | 95 |
| 2016 | 47 |
| 2017 | 38 |
| 2018 | 68 |
| 2019 | 129 |
| 2020 | 78 |
| 2021 | 153 |
| 2022 | 251 |
| 2023 | 192 |
| 2024 | 178 |
| 2025 | 223 |
| 2026 | 200 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,500 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission in errorSignal | 162 | 72.9 | 63.0 | 11,373 |
| weight increasedSignal | 175 | 9.9 | 8.6 | 1,408 |
| dyspepsiaSignal | 54 | 7.0 | 5.4 | 271 |
| weight decreasedSignal | 150 | 6.8 | 5.9 | 748 |
| product dose omission issueSignal | 76 | 3.3 | 2.6 | 120 |
| covid-19Signal | 42 | 3.0 | 2.3 | 56 |
| nasopharyngitisSignal | 41 | 2.8 | 2.1 | 47 |
| fallSignal | 53 | 2.0 | 1.5 | 27 |
| arthralgia | 53 | 1.6 | 1.2 | 12 |
| fatigue | 79 | 1.3 | 1.0 | 5 |
| dizziness | 45 | 1.1 | 0.9 | 1 |
| nausea | 51 | 0.8 | 0.6 | 2 |
| diarrhoea | 41 | 0.8 | 0.6 | 2 |
| headache | 39 | 0.8 | 0.6 | 2 |
| off label use | 43 | 0.6 | 0.5 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.